Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Flunisolide · 1 trial · 1 indication
EARNS-Q Preference Module consists of efficacy, sensory perception (SP), device characteristic (DC), spray delivery (SD), overall product preference (OPP) and total domain. TSQM consists of global satisfaction (GS), convenience, effectiveness and side-effects (SE) domains. Positive (+ve) correlation of EARNS-Q preference scores with change on TSQM domains indicate that preference for a product is associated with better TSQM scores. Negative (-ve) correlation with mean daily rTNSS indicate that preference for a product is associated with lower mean daily rTNSS. Change in TSQM domain scores and mean daily rTNSS was calculated as scores in Treatment Period (TP) 2 minus scores in TP1; change in TSQM is +ve, product in TP2 is preferred, vice-versa; change in rTNSS is -ve, product administered in TP2 is preferred, vice-versa.
The 28 items of the EARNS-Q experience module assess 14 attributes with regard to their product rating and their importance of efficacy, SP, DC and SD. The EARNS-Q preference module consists of additional 15 items that evaluate preference by comparing two products based on the same 14 experience attributes as well as on OPP. Change in EARNS-Q Experience Module domain scores was calculated as scores in TP2 minus scores in TP1. If the change in EARNS-Q Experience Module domain scores is +ve, product in TP2 is preferred and vice-versa. A higher product rating for one of the sprays lead to a preference for that spray. The EARNS-Q preference module was assessed only once, at the end of TP2. Positive correlations indicate agreement (i.e. preference for a product is positively associated with better experience with same product).
| Name | Type | Description |
|---|---|---|
| Beclomethasone dipropionate | DRUG | Beclomethasone dipropionate |
| Flunisolide | DRUG | Flunisolide |
Inclusion criteria: * Seasonal allergic rhinitis. * Nasal allergy symptoms during the spring allergy season. Exclusion Criteria: * Prior use of beclomethasone dipropionate or flunisolide. * Significant concomitant medical conditions. * Use of corticosteroids. * Use of allergy and other identified...
Flunisolide is used for perennial allergic rhinitis, a condition involving year-round nasal allergy symptoms. It is a small molecule respiratory drug being developed by GSK plc. The drug is currently in Phase 3 clinical development, though it remains investigational and has not been approved for this use.
Flunisolide is being developed by GSK plc, a pharmaceutical company listed on the stock exchange under the ticker GSK. The drug is in Phase 3 clinical development for perennial allergic rhinitis, a respiratory condition. GSK is conducting trials to evaluate the drug's effects in patients with this condition.
Flunisolide is in Phase 3 clinical development. It is being studied for the treatment of perennial allergic rhinitis, a respiratory condition. The drug is investigational and not yet approved, as it is still undergoing clinical trials to assess its safety and efficacy in patients.
Flunisolide has one completed Phase 3 clinical trial with the identifier NCT00346775. This trial, titled 'Validation Of Preference Module Of Experience With Allergic Rhinitis Nasal Sprays Questionnaire (EARNS-Q)', enrolled 97 participants in the United States. The study focused on patients with perennial allergic rhinitis and was not blinded or controlled.
Flunisolide is not FDA approved for perennial allergic rhinitis. It is currently in Phase 3 clinical development, meaning it is still being studied in clinical trials. The drug has completed one Phase 3 trial, but approval status has not been established, and it remains an investigational product.